トランスキャセータ性大動脈弁義肢の変形: 低衰弱性小葉片の加厚への影響と臨床的結果
Miho Fukui1,2, Vinayak N Bapat3,2, Santiago Garcia3,2
1Cardiovascular Imaging Research Center and Core Laboratory (M.F., G.H., J.L.C.), Minneapolis Heart Institute Foundation, MN.
Circulation
|July 21, 2022
まとめ
トランスキャテーテルによる大動脈弁置換 (TAVR) の後の義肢枠の変形は,死亡リスクを増大する低衰弱性小葉書 (HALT) と関連しています. TAVRの導入とバルブ設計を最適化することで,患者の治療結果が改善される可能性があります.
科学分野:
- 心血管イメージング
- 介入心臓科
- バイオマテリアル科学
背景:
- トランスキャテーター大動脈弁置換 (TAVR) は,ヒポアテンチュエーション・リーフレット加厚 (HALT) に関する懸念が高まっている治療法です.
- HALTは,義肢の機能と長期的な耐久性に悪影響を及ぼします.
- この研究では,TAVR義肢枠因子とHALT発生の関係が調査されています.
研究 の 目的:
- TAVRにおける義肢枠因子を調べる
- HALTの発生率とこれらの要因を相関させる.
- HALTと臨床結果の関連性を評価する.
主な方法:
- SAPIEN3またはEVOLUT TAVRを投与された患者565人を対象とした前向きな研究.
- 手術の30日後にHALTの心臓コンピュータトモグラフィー検査
- TAVR義肢の変形,フリートアシンメトリー,シヌス体積,およびコンシューラルの整合の分析
主要な成果:
- HALTはSAPIEN3患者の21%とEVOLUT患者の16%で発生した.
- HALTは,より大きな義肢枠の変形,パンフレットアシンメトリー,およびより小さなネオシヌス体積 (P<0. 001) と関連付けられました.
- TAVRの義肢変形は,臨床的要因とは無関係にHALTを予測した. HALTは,1年間の死亡率 (全原因,心臓病) と心不全の入院率の増加と関連していました.
結論:
- 非均一なTAVR義肢の拡張は,フレームの変形,非対称な小葉書,および小さなネオシヌスボリュームにつながり,HALTと関連しています.
- これらの発見は,TAVR義肢の設計と展開技術への影響を示唆しています.
- TAVR患者の臨床的結果を改善する可能性がある.
関連する概念動画
Mitral Valve Prolapse I: Introduction
37
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
37
Mitral Valve Prolapse II: Assessment and Management
39
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
39
Aortic Regurgitation III: Medical Management
38
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
38
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
50
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
50
Aortic Regurgitation I: Introduction
35
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
35
Mitral Stenosis III: Medical Management
18
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
18


